Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Plants of Epilobium angustifolium are popular in China to treatment of traumatic injury, subduing inflammation and menstrual disorders. In European, the preparations or extracts containing E. angustifolium are popular to treat prostate diseases. Recent research suggested that E. angustifolium showed therapeutic effects in early stage of BPH, inflammation of urethra and prostate, as well as micturition problems. And the related researches were focus on aqueous extract and its main constituent of oenothein B.AIM OF THE STUDY: This study aims to evaluate the therapeutic effect against BPH of the ethyl acetate extracts (EAE) and n-butanol extracts (BUE) from E. angustifolium and to chemical investigation of the active constituents.MATERIALS AND METHODS: The in vitro anti-BPH activity was assessed by determining the benign prostatic hyperplasia epithelial-1 (BPH-1) cell viability using MTT assay as well as suppressing of prostate specific antigen (PSA) secretion in prostate epithelial cancer hormone-dependent (LNCaP) cells measured by ELISA method. The in vivo anti-BPH was evaluated by testosterone propionate induced BPH SD rats. After oral administration of BUE at 100, 200 and 400 mg/kg B.W. for 28 days, the prostate weight and index, plasma androgen level, histopathological alteration, oxidative and inflammatory-related factors in prostate were assessed. Phytochemical investigation on active extracts was carried by chromatographic and spectroscopic techniques. Anti-BPH activities of the isolates were evaluated in vitro.RESULTS: BUE and EAE from E. angustifolium exhibited significant anti-BPH effect in vitro. Further in vivo study demonstrated that BUE exhibited therapeutic effects against TP-induced BPH in SD rats via down-regulating of the androgen level, suppressing the expression of NF-κB and eventually alleviating the inflammatory responses and oxidative stress. Phytochemical research on BUE and EAE extracts led to the isolation and identification of 50 compounds. In vitro anti-BPH screening revealed that 26 compounds exhibited anti-proliferation in BHP-1 cell and 36 compounds showed PSA inhibition in LNCap cell, in which 7 compounds exhibited very significant anti-BPH activities in both two cell lines (P < 0.01), 5 compounds with extremely significant activities in one of the cell lines (P < 0.001), and compound 25 exhibited the most potent anti-BPH activity (P < 0.001).CONCLUSIONS: E. angustifolium exhibited the therapeutic potential against BPH, and its active compounds may be used as candidate for treatment of BPH.

Isolation and Identification of Active Compounds on Benign Prostate Hyperplasia from Oiltea camellia Extract

Screening for Aromatase Ligands in the Extract of Broussonetia Papyrifera Using High Performance Liquid Chromatography and ESI-mass Spectrometry

Bioactive constituents from the leaves of Metapanax delavayi with anti-benign prostatic hyperplasia activities

Active Constituents of Urtica Fissa in Inhibition of Benign Prostatic Hyperplasia

Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.

Chemical Profiles of the Active Fraction from Prinsepia Utilis Royle Leaves and Its Anti-Benign Prostatic Hyperplasia Evaluation in Animal Models

Application Of An Efficient Strategy For Discovery And Purification Of Bioactive Compounds From Chinese Herbal Medicines, A Case Study On The Puerariae Thomsonii Flos

Chemical Components from Metapanax Delavayi Leaves and Their Anti-Bhp Activities in Vitro.

The Therapeutic Effects of Docosahexaenoic Acid on Oestrogen/androgen-Induced Benign Prostatic Hyperplasia in Rats

Flavonoids from Campylotropis Hirtella (franch.) Schindl. and Their Bioactivities

The Bioactive Alkaloids Identified from Cortex Phellodendri Ameliorate Benign Prostatic Hyperplasia Via LOX-5/COX-2 Pathways.

Studies on Chromatographic Fingerprint and Fingerprinting Profile-Efficacy Relationship of Saxifraga stolonifera Meerb.

Characterization of Compounds Acting on the Α1a Adrenergic Receptor Fromcaulis Spatholobiby Cell Membrane Chromatography with Possible Application for Treatment of Benign Prostatic Hyperplasia

Bioactivity guided isolation and identification of phenolic compounds from Citrus aurantium L. with anti-colorectal cancer cells activity by UHPLC-Q-TOF/MS

Bioassay-guided isolation of two antiproliferative metabolites from Pterocarpus indicus Willd. against TGF-β-induced prostate stromal cells (WPMY-1) proliferation via PI3K/AKT signaling pathway

Separation and identification of myrrh sesquiterpenoids and their anti-proliferation effect on tumor cells

Network pharmacology and experimental validation to explore the pharmacological mechanism of saw palmetto and its core ingredients in benign prostatic hyperplasia treatment

Deciphering anti-benign prostatic hyperplasia potential of liangwanoside II based on metabolite profile characterization combined with targeted network pharmacology

Secondary Metabolites from Commiphora Opobalsamum and Their Antiproliferative Effect on Human Prostate Cancer Cells.

A strategy based on liquid-liquid-refining extraction and high-speed counter-current chromatography for the bioassay-guided separation of active compound from Taraxacum mongolicum

Ultrasonication assisted percolation extraction, isolation, identification and in silico studies of secondary metabolites from Caesalpinia bonduc (L.) Roxb. seeds with special reference to the target proteins involved in Benign Prostatic Hyperplasia